Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121


Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer.

Al-Sohaily S, Henderson C, Selinger C, Pangon L, Segelov E, Kohonen-Corish MR, Warusavitarne J.

Histopathology. 2014 Aug;65(2):155-63. doi: 10.1111/his.12295. Epub 2014 May 12.


Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.

Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlén M, Jirström K, Eberhard J.

Diagn Pathol. 2012 Aug 30;7:115. doi: 10.1186/1746-1596-7-115.


SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma.

Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Kuteeva E, Johannesson H, Jirström K, Eberhard J.

Virchows Arch. 2014 Dec;465(6):649-59. doi: 10.1007/s00428-014-1667-6. Epub 2014 Oct 19.


Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues.

Kowalczyk AE, Godlewski J, Krazinski BE, Kiewisz J, Sliwinska-Jewsiewicka A, Kwiatkowski P, Pula B, Dziegiel P, Janiszewski J, Wierzbicki PM, Kmiec Z.

Tumour Biol. 2015 Jun;36(6):4441-52. doi: 10.1007/s13277-015-3084-0. Epub 2015 Jan 21.


SATB1 is an independent prognostic marker for gastric cancer in a Chinese population.

Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q.

Oncol Rep. 2010 Oct;24(4):981-7.


Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma.

Niu Y, Wang L, Cheng C, Du C, Lu X, Wang G, Liu J.

APMIS. 2015 Feb;123(2):93-101. doi: 10.1111/apm.12310. Epub 2014 Sep 25.


Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.

Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR.

J Thorac Oncol. 2011 Jul;6(7):1179-89. doi: 10.1097/JTO.0b013e31821b4ce0.


The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer.

Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG.

World J Surg Oncol. 2007 Mar 9;5:31.


Expression of SATB1 promotes the growth and metastasis of colorectal cancer.

Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B, Zhao M, Wei M, Ye C, Sun Y, Yuan X, Yang C, Hao C.

PLoS One. 2014 Jun 27;9(6):e100413. doi: 10.1371/journal.pone.0100413. eCollection 2014.


Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.

Wangefjord S, Brändstedt J, Lindquist KE, Nodin B, Jirström K, Eberhard J.

Diagn Pathol. 2013 Jan 21;8:10. doi: 10.1186/1746-1596-8-10.


Overexpression of special AT-rich sequence-binding protein 1 in endometrial cancer: a clinicopathologic study.

Zhang Y, Wang L, Liu Y, Meng F, Wang S, Shang P, Gao Y, Chen X.

Int J Gynecol Cancer. 2015 Jan;25(1):4-11. doi: 10.1097/IGC.0000000000000314.


SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo.

Zhang J, Zhang B, Zhang X, Sun Y, Wei X, McNutt MA, Lu S, Liu Y, Zhang D, Wang M, Lin Z, Niu N.

PLoS One. 2013;8(1):e47902. doi: 10.1371/journal.pone.0047902. Epub 2013 Jan 11.


Aberrant expression of sphingosine-1-phosphate receptor 1 correlates with metachronous liver metastasis and poor prognosis in colorectal cancer.

Lin Q, Wei Y, Zhong Y, Zhu D, Ren L, Xu P, Zheng P, Feng Q, Ji M, Lv M, Liang C, Xu J.

Tumour Biol. 2014 Oct;35(10):9743-50. doi: 10.1007/s13277-014-2267-4. Epub 2014 Jun 28.


A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.

Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlén M, Ericson Lindquist K, Jirström K.

Br J Cancer. 2012 Feb 28;106(5):931-8. doi: 10.1038/bjc.2012.34. Epub 2012 Feb 14.


Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer.

Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL, Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, Qiu MZ, Luo HY, Zhang DS, Xu RH.

World J Gastroenterol. 2014 Dec 28;20(48):18404-12. doi: 10.3748/wjg.v20.i48.18404.


DEK over expression as an independent biomarker for poor prognosis in colorectal cancer.

Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z.

BMC Cancer. 2013 Jul 31;13:366. doi: 10.1186/1471-2407-13-366.


Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features.

Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q.

APMIS. 2010 Nov;118(11):855-63. doi: 10.1111/j.1600-0463.2010.02673.x. Epub 2010 Sep 2.


p42.3: a promising biomarker for the progression and prognosis of human colorectal cancer.

Yuan XS, Zhang Y, Guan XY, Dong B, Zhao M, Mao LL, Lu YY, Tian XY, Hao CY.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1211-20. doi: 10.1007/s00432-013-1434-0. Epub 2013 Apr 11.


Podocalyxin is a marker of poor prognosis in colorectal cancer.

Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O, Haglund C.

BMC Cancer. 2014 Jul 8;14:493. doi: 10.1186/1471-2407-14-493.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk